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Introduction. Cardiovascular Diseases (CD) have emerged as a lead-
ing cause of morbidity and mortality in HIV population. Some stud-
ies have reported higher carotid Intima Media Thickness (c-IMT), a 
measure of subclinical atherosclerosis (AT), in this cohort of patients. 
Methods. Here, we evaluate the role of Hepatic Steatosis (HS) as 
likely marker for AT in 128 HIV-infected patients without  hepati-
tis C infection. c-IMT has been detected non-invasively by carotid 
ultrasonography to assess the progression of AT. HS has been 
evaluated using a process based on vibration-controlled transient 
elastography (Fibroscan) by a novel ultrasonic controlled attenu-
ation parameter (CAP). The cut-off value for defining the pres-
ence of significant HS was CAP > 259 dBm-1.
Results. AT has been detected in 26 patients (20.3%), whereas 
steatosis of grade 2 (S2) in 31 (24.2%). The variables statistically 
related to AT were age, obesity, diabetes, hypertension and S2. In 
the multivariate analysis, AT was only associated (p < 0.001) with 
age and S2. The optimal cut-off value indicated by ROC curve for 
predicting AT was CAP > 250 dB/m-1.
Discussion. Our results highlight the presence of AT in HIV-
infected persons and its association with fatty liver disease; 
therefore, HS assessment in HIV population results crucial to 
predict AT and CD. 
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Summary
Introduction
Since the advent of highly active anti-retroviral therapy 
(HAART), the prognosis of HIV infection has been dra-
matically altered, transforming it from an inexorably fa-
tal disease into a manageable chronic condition [1, 2].
In this context, cardiovascular diseases (CD) result an 
important cause of morbidity and mortality [3, 4]. Ath-
erosclerosis (AT), a complex, active and progressive dis-
ease with inflammation involved at every stage, is close-
ly correlated to an increased risk of heart diseases [5].
Epidemiological data show a relationship between HIV 
and AT, in fact in the last few years AT prevalence has 
increasingly been found in this cohort of patients [6].
Several factors may contribute to its development among 
HIV-infected individuals. First and foremost the role of 
inflammation has been recognized as the key pathologic 
process [7, 8]. Furthermore, other determinants includ-
ing dyslipidemia, lipodystrophy, insulin resistance, to-
bacco abuse, and metabolic and mitochondrial dysfunc-
tions may be involved in AT disease [9-13]. Previous 
researches have demonstrated an association between 
various components of HAART and the development of 
AT, as well  [14, 15]. Finally, HIV infection itself may 
lead AT via monocyte or T-cell activation and likewise 
concomitant infections in the HIV-infected subjects 
could also promote this process [16, 17].
Epidemiological studies have showed strong associa-
tion between AT and hepatic steatosis (HS) [18, 19]. The 
latter is a clinical condition associated with inflamma-
tion and hepatocyte changes [20]. The different grade 
of steatosis (S) is defined as S0 = 0-10%; S1 = 11-33%; 
S2  =  34-66% and S3  =  67-100% of hepatocytes that 
have a fatty accumulation [21]; it can also be a co-factor 
in many chronic liver diseases that can lead to fibrosis, 
cirrhosis and hepatocellular carcinoma, as well as the 
possibility of developing metabolic alterations that can 
lead to AT [22, 23].
Mounting evidence suggests that HS is common among 
HIV-infected individuals with or without HCV co-in-
fection [24, 25], though data on factors associated with 
steatosis in HIV-mono-infected patients are scarce [26].
To date, liver biopsy is considered the gold standard for 
the assessment of HS [27]. But recently, ultrasound-
based vibration-controlled transient elastography device 
has been developed to detect it [28] using controlled at-
tenuation parameter (CAP). This tool is a non-invasive, 
quantitative, non-ionizing and inexpensive method that 
provides immediate results and it can be performed by 
an operator without specific radiological competence 
and individual interpretation. Furthermore, CAP is able 
to explore a liver volume ~ 100 times larger than liver 
biopsy [21].
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Measurement of AT activity results fundamental for ear-
ly detection of CD [29]. It can be detected non-invasively 
by carotid ultrasonography to assess carotid Intima Me-
dia Thickness (c-IMT) [30, 31]. IMT is a characteristic 
of arterial aging related to AT; the cellular and molecular 
alterations that underlie IMT are implicated in the devel-
opment, progression or both of AT [32]. c-IMT is widely 
used as a validated marker for subclinical atherosclero-
sis in HIV-negative populations [33, 34]; moreover, its 
value greater than or equal to the 75th percentile for age, 
sex and ethnicity has been associated with an increased 
risk of CD [32]. For its low cost and the absence of ex-
posure to radiation, this technology has also been used to 
identify the predictors of subclinical AT in HIV-infected 
individuals [10, 35, 36].
Few data are available on the relationship between AT 
and HS in HIV subjects and since fatty liver diseases 
are common among this population [37], determin-
ing the link with AT may be useful for predicting CD 
risk [38, 39].
Therefore, objective of our study is to evaluate this rela-
tionship in a cohort of HIV patients without concomitant 
hepatitis C virus (HCV) infection.
Methods
Patients
We performed a cross-sectional study by consecutively 
enrolling HIV-infected outpatients from January to June 
2012. All patients approached for the study gave consent 
to participate.
Exclusion criteria were: age less than 18 years, HCV in-
fection, liver cirrhosis, active psychiatric disorders, alco-
holism and drug abuse.
At enrolment time the following demographic, clinical 
and laboratory variables were collected for each subject 
through a patient interview (using a predefined form) 
and a chart review: gender, age, ethnicity, duration of 
HIV infection, CD4 cell count, nadir CD4, HIV viral 
load, therapy, CD risk factors (current smoking habit; 
obesity, defined as a body mass index above or equal 
to 30 kg/m2; diabetes, defined as fasting plasma glucose 
(FPG) levels above 126 mg/dl; hypertension, defined as 
blood pressure (BP) above 140/90 mmHg and/or treat-
ment with antihypertensive medications; dyslipidemia, 
characterized by increased plasma concentration of tri-
glycerides, reduced high-density lipoprotein cholesterol 
and increased numbers of small, dense low-density lipo-
protein particles).
Ultrasonography examination
A Logiq 5 ultrasound scanner (General Electric Medical 
Systems, Wallingford, Connecticut, USA) was used to 
determine AT defined as c-IMT > 0.9 mm. The c-IMT 
was defined as the distance between media-adventitia 
and lumen-intima interfaces and it was measured at 
about 1 cm proximal to the bifurcation of the common 
carotid artery using a 7.5 MHz linear probe. The probe 
was placed so that the near and far walls were parallel 
to it and lumen diameter was maximized in the longitu-
dinal plane. Mean common c-IMT was defined as mean 
IMT of the right and left common carotid arteries, calcu-
lated after 3 measurements on each side. 
The patients were placed in the supine position with 
their head in the midline position, tilted slightly upwards 
and the heart in systole. Sonographic evaluations were 
performed by a single trained sonographer blinded to the 
patients’ data [40].
Fibroscan examination
In all patients the liver steatosis was evaluated by CAP 
measuring ultrasonic attenuation in the liver at 3.5 MHz 
using signals acquired by the FibroScan M probe (Fi-
broscan 502, Echosens, Paris, France) based on vibra-
Tab. I. Baseline characteristics: Demographics, HIV factors, clinical characteristics of HIV patients (N = 128).
Variable n (%) Range
Male sex 92 (71.9)
Age, years* 44 37-49
Ethnicity, Caucasian 123 (96.0)
Smoke use 52 (40.6)
Duration of HIV infection, years * 11 5-16
Current CD4, cells/mm3* 543 360-700
Nadir CD4, cells/mm3* 233 112-313
HIV RNA <20 cp/ml 107 (83.5)
Current cART 128 (93.7)
Duration of cART, years* 8 4-13
Obesity (BMI≥30 kg/m2) 8 (6.2)
Diabetes (FPG>126 mg/dl) 7 (5.4)
Hypertension (BP>140/90 mmHg) 23 (17.9)
Dyslipidemia 101 (78.9)
Atherosclerosis (IMT > 0.9 mm) 26 (20.3)
S2 31 (24.2)
*median (interquartile range); BMI, body mass index
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tion-controlled transient elastography. The principles 
have been described elsewhere [28]. An elastographic 
evaluation has been performed by a single trained so-
nographer blinded to patients’ data. S2 was defined as 
CAP  >  259 dBm-1 according to previously published 
data demonstrating that this cut-off was the most dis-
criminating value [21].
Statistical analyses
The factors associated with AT were identified by logis-
tic univariate regression analysis. The variables showing 
a p-value < 0.100 in the univariate analysis were evaluat-
ed in a multivariable analysis afterwards. The ROC (Re-
ceiver Operating Characteristic) curve and correspond-
ing AUC (Area Under Curve) were calculated in order to 
evaluate the CAP cut-off value able to predict AT.
A two-tailed p-value < 0.05 was considered statistically 
significant. Statistical calculations were performed with 
MedCalc software, version 11.6.0.0.
Results
In total, 128 patients [71.9% males, median age 44 years 
(IQR 37-49), median CD4 543 cells/µl, (IQR 360-700), 
83.5% with HIVRNA < 20 cp/ml] were enrolled.
At enrollment time, 93.7% of patients were receiving 
ART and were using it for an average of 8 years (IQR 
4-13). Obesity was diagnosed in 8 patients (6.2%), 
diabetes mellitus in 7 (5.4%) and hypertension in 23 
(17.9%). Instead, dyslipidemia was detected in a large 
proportion of patients (78.9%) (Tab. I).
26 (20.3%) patients had AT while 31 (24.2%) subjects 
had liver S2 (Table I). HS was observed in 12 patients 
(11.8%) considering the subjects (n = 102) without AT, 
whereas among those (n = 26) with AT, 19 patients had 
also S2 (73.1%). Subjects with AT showed a higher sig-
nificant difference (p < 0.001) of S2 than those without 
AT. 
In univariate analysis, age (5.80, CI 1.8-19.5), obesity 
(15.0, CI 2.8-79.7), diabetes (6.0, CI 1.3-28.7), hyper-
tension (3.90, CI 1.5-5.3), and liver S2 (20.3, CI 7.0-
58.4) were significantly associated with  subclinical AT 
(Tab. II).
In the multivariate model, subclinical AT was associated 
with age [odds ratio (OR) 5.8; p < 0.001] and liver S2 
(OR 20.3; p < 0.001). ROC curve indicated that the most 
discriminant CAP value for predicting AT was  >  250 
dB/m-1 (AUC  =  0.92, sensitivity 92.31%, specificity 
81.37%, p < 0.0001) (Fig. 1).
Discussion 
Several reports have shown that CD and in particular AT 
are common among HIV infected patients [29, 41, 42].
In this cross-sectional study, conducted in a cohort of 
HIV-infected subjects receiving care at the Infectious 
Disease Department in a tertiary hospital in southern 
Italy, 20.3% of the study population was affected by AT. 
These results, similar to those of other studies, underline 
the importance of CD in this group, also with regard to 
Tab. II. Factors associated with atherosclerosis.
Variable
Univariate analysis
OR (95% CI)
p
Multivariate analysis
OR (95% CI)
p
Male sex 1.78 (0.68-4.70) 0.23
Age 5.80 (1.8-19.5) 0.004 5.8 (2.2-24.5) < 0.001
CD4 at nadir (per 100 cells increase) 1.08 (0.90-1.42) 0.29
CD4 cells count (per 100 cells increase) 0.99 (0.78-1.13) 0.66
HIVRNA < 20 cp/ml 0.44 (0.05-1.67) 0.26
Current smoking 1.25 (0.5-13) 0.62
Obesity (BMI≥30 kg/m2) 15.0 (2.8-79.7) 0.005 5.82 (0.6-39.5) 0.14
Diabetes
(FPG > 126 mg/dl)
6.0 (1.3-28.7) 0.02 2.5 (2.3-20.7) 0.30
Hypertension (BP > 140/90 mmHg) 3.90 (1.5-5.3) 0.005 2.14 (0.53-8.6) 0.28
Dyslipidemia 3.80 (0.9-17.6) 0.07 4.39 (0.45-42.7) 0.20
S2 20.3 (7.0-58.4) <0.001 20.3 (4.5-60.1) < 0.001
Fig. 1. ROC curve.
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age; therefore, to address this issue is important for nor-
malizing the life expectancy of HIV population [43, 44].
In our study, we have found that 24.2% of HIV-infected 
subjects had S2, 78.9% dyslipidemia and 17.9% were 
affected by hypertension. Our results regarding the uni-
variate analysis have shown that age, diabetes, hyper-
tension, obesity and S2 were associated with AT. This 
correlation did not remain significant in multivariate 
analysis unless age and S2. 
The elevated prevalence of CD and its correlation with age 
suggest that HIV patients may present accelerated vascu-
lar aging [44]. Nevertheless further studies are needed to 
clarify the mechanisms unrelated to natural aging process.
Furthermore, the study has shown an association be-
tween carotid AT disease and S2, and the CAP val-
ue > 250 dB/m-1 discriminant in predicting AT has been 
detected. Thus, in patients with a value higher than the 
discriminant CAP value, an early evaluation of c-IMT 
may be strongly recommended.
Previous studies on the correlation between fatty liver 
disease and CD have displayed a prevalence of fatty liver 
of 37% and 13% in population with coronary artery dis-
ease [44, 45], versus 73.1% founded in our study. 
The cause-effect relationship between these two factors 
still remains confusing, but the inflammatory state may 
be the common risk factor for AT [46].
The ultrasonographic system used to measure c-IMT 
seems a well-established method for assessing sub-
clinical AT in the HIV-negative population and it is the 
only non-invasive imaging recommended by the Ameri-
can Heart Association for risk assessment for CD [47]. 
Moreover, c-IMT may be a useful methodology to eval-
uate the intima-media thickening implicated in the de-
velopment and progression of atherosclerotic disease in 
HIV patients, as well [40, 48].
Our study have several strengths, in fact to the best of 
our knowledge, it is one of the few studies that exam-
ines the association between fatty liver disease and AT 
in HIV-infected persons.
Furthermore, the results of this paper may have impor-
tant clinical implications. The elastography, used to de-
tect HS, is a useful tool not dependent on operator skill 
and does not expose the patient to ionizing radiation. 
Other advantages of CAP include its simplicity, accurate 
quantification, inexpensive and sensitivity to lesser de-
grees of HS [49]. Therefore, its use in the normal clinical 
routine could be strongly recommended.
Weaknesses of the research include the cross-sectional 
design, therefore prospective studies might be appro-
priate to evaluate the progression of fatty liver disease 
in CD. Moreover, the sample size was limited to arrive 
at definite conclusions, thus the study needs to be con-
firmed in a larger population. The assessment of inflam-
matory markers to explain the association between HIV 
serostatus and c-IMT should be included in future studies 
also consequently to conflicting evidences founded [50].
In summary, HIV-infected populations have a high preva-
lence of subclinical AT. Moreover, AT is associated with 
fatty liver disease and HS assessment results crucial 
both in clinical practice for management of patients with 
chronic liver disease and for reducing risk factors, and 
in clinical research for epidemiological and therapeutic 
studies. 
Early identification of CD risk in HIV patients could 
permit to modify lifestyle and to take therapeutic mea-
sures in order to prevent or delay the onset of chronic 
diseases difficult to manage.
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